Tag Archives: Targeted medical pharma

Targeted Medical Pharma Combats the Epidemic of Pain with Release of THERALEVE™

Los Angeles, — Targeted Medical Pharma, Inc. (OTCQB: TRGM) in conjunction with Amino Nutritionals LLC, today announced the consumer release of THERALEVE™ (www.theralevehealth.com) a patented amino acid based formula designed by pain management physicians to help the 100 million chronic pain sufferers in the United States, fight pain and inflammation without the dangerous side effects commonly associated with NSAIDs and opioids. “Common pain medications do not address the nutritional needs of the nervous system and only target symptoms of pain. THERALEVE provides a specific blend Continue reading →

Research Identifies a Potential New Path to Developing a Treatment for Chronic Pain

Los Angeles, September 8, 2015 – Targeted Medical Pharma to present new chronic pain research that reveals significant nervous system abnormalities among patients suffering from Fibromyalgia, at the 2015 PainWeek national conference in Las Vegas, Nevada. The study looked at 329 Fibromyalgia patients and 58 control patients all of whom wore Holter monitors for a 24 hour period to measure nervous system activity. The results of this study showed that patients with Fibromyalgia experience a significant decrease in both nighttime parasympathetic nervous system (PNS) activity and daytime sympathetic Continue reading →

New Research Finds a Link Between Obesity and Nutritional Deficiencies

Los Angeles, CA, April 27, 2015 — Obesity has reached epidemic proportions affecting nearly 78 million adults in the United States and has been linked with an increased risk of diabetes, heart disease, and cancer. Recent studies have suggested that obese patients have specific amino acid deficiencies that can contribute to obesity. The latest research report entitled “Nutritional Deficiencies Associated with Obesity,” published online in the Journal of Obesity and Weight Loss Therapy, highlights the specific amino acid and nutrient deficiencies that are commonly associated Continue reading →

Targeted Medical Pharma Announces Changes in Management and Board of Directors

New Management Structure Positions Company for Growth and Profitability Los Angeles, CA, January 29, 2015 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced several major changes that streamline operations and signify a commitment to revenue growth, cost containment and profitability. The Company has appointed Kim Giffoni, a co-founder and former Vice President of Foreign Sales at Targeted Medical Pharma, as the Chief Executive Officer. Dr. David Silver, former Chief Operating Officer and President at the Company, has been appointed Chief Medical Officer, and Marcus Continue reading →

Clinical Trial Results Confirm Amino Acid Based Medical Food Theramine® More Effective at Improving Chronic Back Pain than NSAID Pain Medications

Los Angeles, CA, September  23, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development company, announced the results of a second, double-blind clinical trial which confirmed that Theramine was shown not only to be more effective than ibuprofen in reducing low back pain, but also demonstrated a significant reduction in measures of inflammation. In this 28 day, multi-center trial, subjects taking Theramine as either a standalone medication or in conjunction with a low dose ibuprofen, demonstrated a significant reduction in both Continue reading →

Targeted Medical Pharma Reports Second Quarter 2014 Financial Results

Los Angeles, CA, August 14, 2014 – Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced financial results for its second quarter ended June 30, 2014.  The Company posted increased revenues, gross profit and an increase in net income before interest, taxes, depreciation and amortization, and stock based compensation (Adjusted EBITDA*) on a quarter-over-quarter basis. Financial Overview Quarter-over-Quarter Comparison: Financial results for the three months ended June 30, 2014 compared to the three months ended June 30, 2013 Total revenue of $2.2 million, a 16% improvement Continue reading →

Targeted Medical Pharma Appoints Two New Independent Members to the Board of Directors

 Health Care Veteran Kerry Weems and Corporate Finance Expert Paul Pelosi, Jr. Join the Advisory Team Los Angeles, CA, June 13, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the addition of two independent members to the Company’s board of directors. The Company welcomes back health care specialist Kerry Weems to the board as an independent director and chairman of the Nominating and Governance Committee, as well as corporate finance expert Paul Pelosi, Jr. as an independent director. A nationally respected expert in Continue reading →

Targeted Medical Pharma Reports First Quarter 2014 Financial Results

Los Angeles, CA, May 21, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and markets medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders announced financial results for its first quarter ended March 31, 2014. William Shell, M.D., Chief Executive Officer and Chief Science Officer of Targeted Medical Pharma stated, “During the remainder of 2014 we will continue to focus on the expansion of sales and marketing efforts to increase Continue reading →

Targeted Medical Pharma Completes Middle East Distribution Agreement

Creates new market opportunity for increased product sales  Los Angeles, April 28,  2014 – Targeted Medical Pharma (OTCQB: TRGM),  announced the completion of an agreement between Analytical Testing Laboratories (ATL), a Lebanon based company that specializes in drug testing services and inborn errors of metabolism,  for the exclusive distribution of the company’s amino acid based products to physicians and pharmacies throughout the Middle East. The Agreement provides ATL with a limited exclusive license for the marketing and sales of certain products in twenty countries in Continue reading →

Targeted Medical Pharma Reports Fourth Quarter and Fiscal Year 2013 Financial Results

Year-Over-Year Revenue Increase of 31% and Gross Profit Increase of 60% for the year ended December 31, 2013 Los Angeles, CA, March 31, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced financial results for its fourth quarter and fiscal year ended December 31, 2013.  The Company posted increased revenues, gross profit and a reduction in net loss before interest, taxes, depreciation and amortization, stock based compensation (Adjusted EBITDA*) on both a year-over-year and a quarterly basis. Financial Overview Year-over-Year Comparison: Improved financial results Continue reading →